Brief: Adocia And Tonghua Dongbao Announce Final Dosing In Phase 3 Clinical Study Of Biochaperone® Lispro

Adocia SA

12/12/2024 17:57

Dec 12 (Reuters) - Adocia SA  ADOC.PA :
    * ADOCIA AND TONGHUA DONGBAO ANNOUNCE THE FINAL DOSING IN A
PHASE
3 CLINICAL STUDY OF BIOCHAPERONE® LISPRO, MILESTONE ASSOCIATED
WITH A $10 MILLION PAYMENT
    * ADOCIA SA - PHASE 3 TOPLINE RESULTS EXPECTED IN H1 2025
    * ADOCIA SA - SECOND STUDY IN TYPE 1 DIABETES NEARING END OF
TREATMENT, EXPECTED TO BE IN EARLY 2025

Source text:  ID:nBw3Ps00Ja 
Further company coverage:  ADOC.PA 

 ((Reuters.Briefs@thomsonreuters.com;))